This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 4, 2012 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO - News), which manufactures and markets the
FC2 Female Condom®, today announced that it will be presenting at the
Sidoti & Company 2012 Semi-Annual New York Micro-Cap Conference on
January 9, 2012. The Conference will be held at The Grand Hyatt in
New York City.
O.B. Parrish, Chief Executive Officer, and
Donna Felch, Chief Financial Officer, will present an overview of The Female Health Company at
2:00 PM Eastern Time on
Monday, January 9, 2012 in the Estate 2 Edison room. The Company's executives will also meet with investors to discuss the Company's ongoing operations.
About Sidoti & Company, LLCSidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard for independent small-cap equity research, while rapidly becoming a driving force in micro-cap research, launching coverage of more than 100 equities of
$200 million market cap or less since inception in mid-2010. Its analysts mine dozens of industries to provide unbiased, institutional-quality research focusing on the investment merits of profitable companies at a sub-
$3 billion market cap, and it anticipates extending coverage to 700 small-cap equities by the end of 2012.
About The Female Health Company
The Female Health Company, based in
Chicago, Illinois, manufactures and markets the
FC2 Female Condom® (FC2), which is available in the U.S. and in about 120 other countries globally. The Company owns certain worldwide rights to the
FC2 Female Condom®, including patents that have been issued in the U.S., the European
The People's Republic of China,
Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes
Uganda, United Republic of
Zambia and Zimbabwe. FC2 patent applications are pending in various countries.
The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: